The irreversible pan-HER inhibitor neratinib (N), which covalently binds to the kinase domain of HER1/EGFR, HER2, and HER4, has shown clinical promise leading to its FDA approval for extended treatment of early-stage HER2+ breast cancer in the adjuvant setting following T-based therapy. This evidence concerns the gene EGFR and breast cancer.